LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Search

Twist Bioscience Corp

Closed

SectorHealthcare

49.55 2.61

Overview

Share price change

24h

Current

Min

48.29

Max

50.63

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+7.13% upside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

347M

2.9B

Previous open

46.94

Previous close

49.55

News Sentiment

By Acuity

50%

50%

167 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

25 Feb 2026, 23:25 UTC

Hot Stocks

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 Feb 2026, 23:15 UTC

Earnings

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 Feb 2026, 23:54 UTC

Market Talk

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 Feb 2026, 23:47 UTC

Earnings

Ferrovial 4Q Net EUR197M >FER.MC

25 Feb 2026, 23:45 UTC

Earnings

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 Feb 2026, 23:42 UTC

Earnings

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 Feb 2026, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 Feb 2026, 23:25 UTC

Earnings

Trip.com: Company's Business Operations Remain Normal >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com FY EPS CNY47.67 >TCOM

25 Feb 2026, 23:06 UTC

Earnings

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 Feb 2026, 23:01 UTC

Earnings

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 Feb 2026, 23:00 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

25 Feb 2026, 23:00 UTC

Market Talk
Earnings

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 Feb 2026, 22:56 UTC

Market Talk
Earnings

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 Feb 2026, 22:43 UTC

Earnings
Acquisitions, Mergers, Takeovers

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 Feb 2026, 22:40 UTC

Market Talk
Earnings

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 Feb 2026, 22:40 UTC

Earnings

Karoon Energy Says Search for New CFO Well Advanced

25 Feb 2026, 22:39 UTC

Earnings

Karoon Energy Says CFO Ray Church to Leave Company

25 Feb 2026, 22:39 UTC

Earnings

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 Feb 2026, 22:38 UTC

Earnings

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

7.13% upside

12 Months Forecast

Average 52 USD  7.13%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

167 / 351 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat